Shou Kit Hang

Shou Kit Hang

Auto-generated profile, based on publicly available information

Shou Kit Hang

T Cell Diagnostics Ptd. Ltd., Singapore

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JLJoey Ming Er Lim
Joey Ming Er Lim
ATAnthony Tanoto Tan
Anthony Tanoto Tan
NBNina Le Bert
Nina Le Bert
SHShou Kit Hang
Shou Kit Hang
JLJenny Guek Hong Low
Jenny Guek Hong Low
ABAntonio Bertoletti
Antonio Bertoletti
Rapid recognition of SARS-CoV-2–infected cells by resident T cells in the upper airway might provide an important layer of protection against COVID-19. Whether parenteral SARS-CoV-2 vaccination or infection induces nasal-resident T cells specific for distinct SARS-CoV-2 proteins is unknown. We isolated T cells from the nasal mucosa of COVID-19 vaccinees who either experienced SARS-CoV-2 infection after vaccination (n = 34) or not (n = 16) and analyzed their phenotype, SARS-CoV-2 specificity, function, and persistence. Nasal-resident SARS-CoV-2–specific CD8+ and CD4+ T cells were detected almost exclusively in vaccinees who experienced SARS-CoV-2 breakthrough infection. Importantly, the Spike-specific T cells primed by vaccination did not suppress the induction of T cells specific for other SARS-CoV-2 proteins. The nasal-resident T cell responses persisted for ≥140 d, with minimal sign of waning. These data highlight the importance of viral nasal challenge in the formation of SARS-CoV-2–specific antiviral immunity at the site of primary infection and further define the immunological features of SARS-CoV-2 hybrid immunity.

3 July 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TSTaraz Samandari
Taraz Samandari
JOJoshua B. Ongalo
Joshua B. Ongalo
KMKimberly D. McCarthy
Kimberly D. McCarthy
RBRichard K. Biegon
Richard K. Biegon
PMPhilister A. Madiega
Philister A. Madiega
ABAntonio Bertoletti
Antonio Bertoletti
Background. SARS-CoV-2 infection in Africa has been characterized by a less severe disease profile than what has been observed elsewhere, but the profile of SARS-CoV-2–specific adaptive immunity in these mainly asymptomatic patients has not, to our knowledge, been analyzed. Methods. We collected blood samples from residents of rural Kenya (n = 80), who had not experienced any respiratory symptoms or had contact with individuals with COVID-19 and had not received COVID-19 vaccines. We analyzed spike-specific antibodies and T cells specific for SARS-CoV-2 structural (membrane, nucleocapsid, and spike) and accessory (ORF3a, ORF7, ORF8) proteins. Pre-pandemic blood samples collected in Nairobi (n = 13) and blood samples from mild-to-moderately symptomatic COVID-19 convalescent patients (n = 36) living in the urban environment of Singapore were also studied. Results. Among asymptomatic Africans, we detected anti-spike antibodies in 41.0% of the samples and T cell responses against 2 or more SARS-CoV-2 proteins in 82.5% of samples examined. Such a pattern was absent in the pre-pandemic samples. Furthermore, distinct from cellular immunity in European and Asian COVID-19 convalescents, we observed strong T cell immunogenicity against viral accessory proteins (ORF3a, ORF8) but not structural proteins, as well as a higher IL-10/IFN-γ cytokine ratio profile. Conclusions. The high incidence of T cell responses against different SARS-CoV-2 proteins in seronegative participants suggests that serosurveys underestimate SARS-CoV-2 prevalence in settings where asymptomatic infections prevail. The functional and antigen-specific profile of SARS-CoV-2–specific T cells in African individuals suggests that environmental factors can play a role in the development of protective antiviral immunity. Funding. US Centers for Disease Control and Prevention, Division of Global Health Protection; the Singapore Ministry of Health’s National Medical Research Council (COVID19RF3-0060, COVID19RF-001, COVID19RF-008, MOH-StaR17Nov-0001).

15 June 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MQMartin Qui
Martin Qui
NBNina Le Bert
Nina Le Bert
WCWebber Pak Wo Chan
Webber Pak Wo Chan
MTMalcolm Tan
Malcolm Tan
SHShou Kit Hang
Shou Kit Hang
ESEnnaliza Salazar
Ennaliza Salazar
BACKGROUND. Patients undergoing immune-modifying therapies demonstrate a reduced humoral response after COVID-19 vaccination, but we lack a proper evaluation of the effect of such therapies on vaccine-induced T cell responses. METHODS. We longitudinally characterized humoral and spike-specific T cell responses in patients with inflammatory bowel disease (IBD), who were on antimetabolite therapy (azathioprine or methotrexate), TNF inhibitors, and/or other biologic treatment (anti-integrin or anti-p40) for up to 6 months after completing 2-dose COVID-19 mRNA vaccination. RESULTS. We demonstrate that a spike-specific T cell response was not only induced in treated patients with IBD at levels similar to those of healthy individuals, but also sustained at higher magnitude for up to 6 months after vaccination, particularly in those treated with TNF inhibitor therapy. Furthermore, the spike-specific T cell response in these patients was mainly preserved against mutations present in SARS-CoV-2 B.1.1.529 (Omicron) and characterized by a Th1/IL-10 cytokine profile. CONCLUSION. Despite the humoral response defects, patients under immune-modifying therapies demonstrated a favorable profile of vaccine-induced T cell responses that might still provide a layer of COVID-19 protection. FUNDING. This study was funded by the National Centre for Infectious Diseases (NCID) Catalyst Grant (FY2021ES) and the National Research Fund Competitive Research Programme (NRF-CRP25-2020-0003).

21 June 2025 in Journal of Hepatology
Verified
Journal Article
Open access
NBNina Le Bert
Nina Le Bert
AKApostolos Koffas
Apostolos Koffas
RKRajneesh Kumar
Rajneesh Kumar
FFFloriana Facchetti
Floriana Facchetti
ATAnthony T. Tan
Anthony T. Tan
PKPatrick T.F. Kennedy
Patrick T.F. Kennedy
There is an unmet need for immunological biomarkers in chronic HBV infection (CHB), where patient management relies on virological and biochemical markers despite the crucial role of virus-specific T cells in controlling viral replication and disease progression. Here, we developed the HBV-cytokine release assay (HBV-CRA), a rapid, point-of-care test, to define whether HBV-specific T cell functional patterns are linked with conventional disease phase classifications. Peptides covering pan-genotype HBV proteomes were utilized to trigger cytokine release by HBV-specific T cells in whole blood. We first assessed the assay's sensitivity by spiking whole blood with engineered HBV-specific T cells. Next, we compared the sensitivity and reproducibility of the HBV-CRA to ex vivo IFN-γ ELISpot assays. We then applied the assay in a cross-sectional study of 235 patients with CHB and longitudinally in patients with acute HBV infection (AHB) during HBsAg seroclearance. The HBV-CRA detected T cell function in 80% of CHB cases and showed that elevated IL-2 and IFN-γ levels after Core peptide stimulation were associated with HBsAg clearance in AHB. Unsupervised clustering identified distinct immune response patterns independent of established clinical and virological classifications and detected a functional impact of NUC treatment on HBV-specific T cell responses. The HBV-CRA is an easy-to-use assay that identifies immune profiles associated with HBsAg clearance in AHB and differentiates patients with CHB based on antiviral T cell function. Importantly, distinct HBV-specific T cell cytokine patterns were detected independently of conventional clinical disease phases, suggesting that stratification of patients with CHB for immunotherapeutic interventions should be guided by the HBV-CRA. Challenges in collecting anti-HBV immune biomarkers from patients with chronic HBV infection (CHB) have led us to develop an easy-to-use assay (HBV-CRA) designed to quantify virus-specific T cell function in patient whole blood. We show that the HBV-CRA can identify immune profiles associated with HBsAg clearance in AHB and reveal functional T cell heterogeneity among patients with CHB that is not captured by standard clinical classifications. By offering a scalable, point-of-care immune monitoring tool, the HBV-CRA could support the development and implementation of personalized immunotherapeutic strategies in CHB management.

18 June 2024 in EBioMedicine
Verified
Journal Article
Open access
MQMartin Qui
Martin Qui
SHSmrithi Hariharaputran
Smrithi Hariharaputran
SHShou Kit Hang
Shou Kit Hang
JZJinyan Zhang
Jinyan Zhang
CTChee Wah Tan
Chee Wah Tan
NBNina Le Bert
Nina Le Bert
Background Hybrid immunity to SARS-CoV-2, resulting from both vaccination and natural infection, remains insufficiently fi ciently understood in paediatric populations, despite increasing rates of breakthrough infections among vaccinated children. Methods We conducted a prospective longitudinal study to investigate the magnitude, specificity, fi city, and cytokine profile fi le of antigen-specific fi c T cell responses elicited by breakthrough SARS-CoV-2 infection in a cohort of mRNA-vaccinated children (n = 29) aged 5-11. - 11. This longitudinal analysis involved six distinct time points spanning a 16-month period post-vaccination, during which we analysed a total of 159 blood samples. All children who were followed for at least 12 months (n = 26) experienced a breakthrough infection. We conducted cytokine release assays using minimal blood samples, and we verified fi ed the cellular origin of these responses through intracellular cytokine staining. Findings After breakthrough infection, children who had received mRNA vaccines showed enhanced Th1 responses specific fi c to Spike peptides. Additionally, their Spike-specific fi c T cells exhibited a distinctive enrichment of CD4+ IFN gamma +IL10+ cells, a characteristic akin to adults with hybrid immunity. Importantly, vaccination did not impede the development of multi-specific fi c T cell responses targeting Membrane, Nucleoprotein, and ORF3a/7/8 antigens. Interpretation Children, previously primed with a Spike-based mRNA vaccine and experiencing either symptomatic or asymptomatic breakthrough infection, retained the ability to enhance and diversify Th1/IL-10 antigen-specific fi c T cell responses against multiple SARS-CoV-2 proteins. These fi ndings mirror characteristics associated with hybrid cellular immunity in adults, known to confer resistance against severe COVID-19. Funding This study was funded by the National Medical Research Council (NMRC) Singapore (COVID19RF-0019, MOH-000019, MOH-000535, OFLCG19May-0034 and MOH-OFYIRG19nov-0002).

1 January 2024 in Immunotherapy Advances
Verified
Journal Article
Open access
PDF file
ATAnthony T Tan
Anthony T Tan
SHShou Kit Hang
Shou Kit Hang
NTNicole Tan
Nicole Tan
TKThinesh L Krishnamoorthy
Thinesh L Krishnamoorthy
WCWan Cheng Chow
Wan Cheng Chow
ABAntonio Bertoletti
Antonio Bertoletti
The clinical efficacy of chimeric antigen and T cell receptor (TCR) T cell immunotherapies is attributed to their ability to proliferate and persist in vivo. Since the interaction of the engineered T cells with the targeted tumour or its environment might suppress their function, their functionality should be characterized not only before but also after adoptive transfer. We sought to achieve this by adapting a recently developed Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapid whole blood T cell assay to stimulate engineered TCR T cells in small volumes of whole blood (<1 ml) without in vitro cellular purification. As a proof-of-concept, we used this method to longitudinally study two patients with primary Hepatitis B Virus (HBV)-related hepatocellular carcinoma who received multiple dose-escalating infusions of transiently functional mRNA-engineered HBV-TCR T cells. We demonstrated that a simple pulsing of whole blood with a peptide corresponding to the epitope recognized by the specific HBV-TCR elicited Th1 cytokine secretion in both patients only after HBV-TCR T cell treatment and not before. The amount of cytokines secreted also showed an infusion-dose-dependent association. These findings support the utility of the whole blood cytokine release assay in monitoring the in vivo function and quantity of engineered T cell products following adoptive transfer.